Emerging Therapy, Unmet Needs & TPP Insights
Obstructive Sleep Apnea (OSA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Delivery: 48-72 Hrs
Therapy area
intelligence
for confident
biopharma
decisions
Global
Schizophrenia
Landscape, and Market Forecast
ESMO 2026,
decoded for
your strategy
Turn complex
epidemiology
into decision-
ready insight
EpiLansis
Patient funnel
Prevalent population
100%
Diagnosed
68%
Treated
44%
Addressable for new therapy
21%
Illustrative data for design preview. Replace with your validated market data.
AI-powered, cloud-based
For scientific, commercial, and strategy teams
Payer insights
in as little as
three weeks
Expert consulting
from pipeline
to launch
Portfolio Optimization
Target Product Profile
(TPP) Analysis
Primary Market Research
(PMR)
Market Forecasting
Health Economics and
Outcomes Research
(HEOR)
Market Access
Conference Coverage
See how we work
Trusted by teams from emerging biotech to global pharma
6,000+
biopharma reports published
1M+
hours of research behind them
10+
years supporting life sciences
1,000+
cumulative years of team experience
What we do
One partner from evidence to strategy
Start with ready-made research, put our platforms to work, or bring us your toughest question. Each step builds on the one before.
01
Step 01
Start with evidence
Reports & Insights
In-depth reports on epidemiology, treatment, competition, access and forecasts for the indications you track.
6,000+
syndicated reports
02
Step 02
Put platforms to work
Strategy Products
AI-powered platforms for epidemiology, payer and analog insights, each backed by analysts who help you act on the results.
350+
indications covered in EpiLansis
03
Step 03
Turn evidence into strategy
Consulting Services
Consultants who take you from choosing an indication to planning a launch, using the same evidence base.
8
services, from pipeline to launch
Not sure where to start?
Tell us your question and we will point you to the right mix of research, platforms and consulting.
Strategy products built
for faster decisions
Three AI-powered platforms, each backed by analysts who help you act on the results.
EpiLansis
Epidemiology and forecasting in one cloud platform
Explore patient populations, disease burden, and treatment landscapes, then turn them into decision-ready forecasts.
- 350+ indications across 35+ global markets
- Patient funnels and patient journey analytics
- Built for scientific, commercial, and strategy teams
Diagnosed prevalence by market
- Lower
- Mid
- Higher
United States
Germany
France
Italy
Spain
United Kingdom
Japan
China
Illustrative preview
PayerPro360
Payer insights in as little as three weeks
Reach the right payers with AI-assisted questionnaires and expert support from study design to final results.
- Global payer network across 31+ markets
- AI-assisted questionnaire design
- Expert interpretation of every finding
Payer perception study
Week 2 of 3
Private payers
25 of 25
Institutional payers
20 of 20
Government payers
8 of 10
Pharmacy specialists
6 of 10
Illustrative preview
Analog Tool
Forecast with evidence from comparable launches
Compare uptake curves from analog products to ground your forecasts and launch expectations.
- ide-by-side analog uptake comparisons
- Benchmarks to sense-check your forecast
- [Add a third key benefit]
Patient share after launch
Analogs
Your asset, projected
Illustrative preview
Reports for the indications
you're tracking
6,000+ reports on epidemiology, competition, treatment, access, and forecasts across the US, EU5, Japan, China, and beyond.
Emerging Therapy, Unmet Needs & TPP Insights
VEXAS Syndrome – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Delivery: 48-72 Hrs
Emerging Therapy, Unmet Needs & TPP Insights
Antiphospholipid Syndrome (APS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Delivery: 48-72 Hrs
Emerging Therapy, Unmet Needs & TPP Insights
Moderate to Severe Asthma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Delivery: 48-72 Hrs
Market Outlook and Forecast
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Delivery: 48-72 Hrs
Market Outlook and Forecast
Spinal Cord Injury (SCI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Delivery: 48-72 Hrs
Tracking several indications?
Bundle reports and get custom pricing.
Consulting that follows your
asset from pipeline to launch
Pick a stage to see how our consultants help.
Therapy area strategy
Assess disease areas for unmet need, competition, and commercial potential.
Indication and asset prioritization
Rank indications and assets by opportunity so investment goes where it counts.
Need support at this stage?
Target product profile analysis
Timely competitive insights from key medical congresses.
Primary market research
Test TPP scenarios against the competitive landscape and stakeholder needs.
Need support at this stage?
Market forecasting
Patient-based forecasts built on validated epidemiology.
Market access
Pricing, HTA, and reimbursement strategy across your launch markets.
Need support at this stage?
Conference coverage
Timely competitive insights from key medical congresses.
Primary market research
Physician, KOL, and payer interviews to validate every decision.
Need support at this stage?
Why Thelansis
Why biopharma teams choose Thelansis
Our name stands for Therapy Area Landscape Analysis, and that focus shapes every engagement.
01
Therapy-area depth
More than a decade of research across rare diseases and oncology.
02
Multidisciplinary team
Epidemiologists, pharmacists, biotechnologists and consultants on every project.
03
Platforms plus people
AI-powered tools backed by analysts who help you interpret the results.
04
Global delivery
Teams in the United States and India serving clients worldwide.
05
Proven track record
6,000+ biopharma reports, built on more than one million hours of research.
06
Payer and access insight
Payer research across 31+ markets with PayerPro360, in as little as three weeks.
Results clients can measure
Case study: PayerPro360
Payer perception study for a cell therapy in a rare indication
Challenge
Understand pricing and reimbursement potential in the US, France, Italy, and Germany.
Approach
65 interviews with private, institutional, and government payers and pharmacy specialists.
“PayerPro360 has significantly streamlined our process.”
VP, Market Access and Pricing, cell and gene therapy company
Key result
50%
less time and resources than the client’s earlier payer studies
Custom research
Can't find the exact report you need?
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
- Built around your indication and markets
- Scoped with our analysts
- A proposal you can share with your team
Build your request
Prefer to talk it through? Email clientsupport@thelansis.com
Thanks, , we have your request
You asked for for covering . We will reply to .
Insights
Latest insights
Analysis from our team on markets, access and launches.
Get therapy area insights in your inbox
A short monthly roundup of new reports and market shifts.
More
More
- Report & Insights
- Strategy Products
Strategy Products
- Consulting Services
- Media
Media
